- Home
- CNTB vs ITRM Comparison
CNTB vs ITRM Comparison
Compare CNTB & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTB
- ITRM
- Stock Information
- Founded
- CNTB 2012
- ITRM 2015
- Country
- CNTB United States
- ITRM Ireland
- Employees
- CNTB N/A
- ITRM N/A
- Industry
- CNTB Biotechnology: Pharmaceutical Preparations
- ITRM Biotechnology: Pharmaceutical Preparations
- Sector
- CNTB Health Care
- ITRM Health Care
- Exchange
- CNTB Nasdaq
- ITRM Nasdaq
- Market Cap
- CNTB 44.2M
- ITRM 40.0M
- IPO Year
- CNTB 2021
- ITRM 2018
- Fundamental
- Price
- CNTB N/A
- ITRM $0.96
- Analyst Decision
- CNTB Strong Buy
- ITRM Strong Buy
- Analyst Count
- CNTB 2
- ITRM 2
- Target Price
- CNTB $7.50
- ITRM $7.00
- AVG Volume (30 Days)
- CNTB 103.1K
- ITRM 532.9K
- Earning Date
- CNTB 05-15-2025
- ITRM 08-13-2025
- Dividend Yield
- CNTB N/A
- ITRM N/A
- EPS Growth
- CNTB N/A
- ITRM N/A
- EPS
- CNTB N/A
- ITRM N/A
- Revenue
- CNTB $26,033,000.00
- ITRM N/A
- Revenue This Year
- CNTB N/A
- ITRM N/A
- Revenue Next Year
- CNTB N/A
- ITRM $270.19
- P/E Ratio
- CNTB N/A
- ITRM N/A
- Revenue Growth
- CNTB N/A
- ITRM N/A
- 52 Week Low
- CNTB $0.51
- ITRM $0.81
- 52 Week High
- CNTB $1.60
- ITRM $3.02
- Technical
- Relative Strength Index (RSI)
- CNTB 72.64
- ITRM 44.42
- Support Level
- CNTB $1.02
- ITRM $0.93
- Resistance Level
- CNTB $1.07
- ITRM $1.03
- Average True Range (ATR)
- CNTB 0.09
- ITRM 0.04
- MACD
- CNTB 0.01
- ITRM -0.00
- Stochastic Oscillator
- CNTB 91.19
- ITRM 26.15
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.